ES2383358T3 - Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal - Google Patents

Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal Download PDF

Info

Publication number
ES2383358T3
ES2383358T3 ES03812100T ES03812100T ES2383358T3 ES 2383358 T3 ES2383358 T3 ES 2383358T3 ES 03812100 T ES03812100 T ES 03812100T ES 03812100 T ES03812100 T ES 03812100T ES 2383358 T3 ES2383358 T3 ES 2383358T3
Authority
ES
Spain
Prior art keywords
cys
peptide
seq
xaa1
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03812100T
Other languages
English (en)
Spanish (es)
Inventor
Richard James Lewis
Paul Francis Alewood
Dianne Alewood
Elka Palant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenome Ltd
Original Assignee
Xenome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenome Ltd filed Critical Xenome Ltd
Application granted granted Critical
Publication of ES2383358T3 publication Critical patent/ES2383358T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES03812100T 2002-12-02 2003-12-02 Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal Expired - Lifetime ES2383358T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43030602P 2002-12-02 2002-12-02
US430306P 2002-12-02
PCT/AU2003/001605 WO2004050690A1 (en) 2002-12-02 2003-12-02 NOVEL χ-CONOTOXIN PEPTIDES (-I)

Publications (1)

Publication Number Publication Date
ES2383358T3 true ES2383358T3 (es) 2012-06-20

Family

ID=32469446

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03812100T Expired - Lifetime ES2383358T3 (es) 2002-12-02 2003-12-02 Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal

Country Status (13)

Country Link
US (1) US7851444B2 (https=)
EP (1) EP1572725B1 (https=)
JP (1) JP4565087B2 (https=)
AT (1) ATE547424T1 (https=)
AU (1) AU2003302609B9 (https=)
CA (1) CA2508129C (https=)
CY (1) CY1112839T1 (https=)
DK (1) DK1572725T3 (https=)
ES (1) ES2383358T3 (https=)
NZ (1) NZ540518A (https=)
PT (1) PT1572725E (https=)
SI (1) SI1572725T1 (https=)
WO (1) WO2004050690A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) * 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
US8062623B2 (en) * 2004-10-15 2011-11-22 Velocys Stable, catalyzed, high temperature combustion in microchannel, integrated combustion reactors
US20070154360A1 (en) * 2005-10-13 2007-07-05 Velocys Inc. Microchannel apparatus comprising a platinum aluminide layer and chemical processes using the apparatus
CN102752032B (zh) 2011-04-22 2015-04-22 艾利森电话股份有限公司 同频负载均衡方法及其设备
WO2016191200A1 (en) * 2015-05-22 2016-12-01 Clemson University Conotoxin peptides for use in biofouling deterrence
CN119462881A (zh) * 2024-12-20 2025-02-18 深圳肽盛生物科技有限公司 μ型芋螺毒素肽及其药物组合物和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051403A (en) 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
AU715165B2 (en) 1994-11-03 2000-01-20 Novartis Ag Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
WO1996040064A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
DE69627153T2 (de) 1995-06-27 2003-12-04 Elan Pharmaceuticals, Inc.(N.D.Ges.D.Staates Delaware) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
CZ288739B6 (cs) 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
WO1998022126A1 (en) 1996-11-18 1998-05-28 University Of Utah Research Foundation USE OF CONOTOXIN PEPTIDES ImI AND MII AS CARDIOVASCULAR AGENTS
WO1998051668A1 (en) 1997-05-14 1998-11-19 Neurosearch A/S Piperidine derivatives as neurotransmitter re-uptake inhibitors
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) * 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
AU3473800A (en) 1999-01-29 2000-08-18 University Of Utah Research Foundation Conotoxin peptides
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20030170222A1 (en) * 2001-01-29 2003-09-11 University Of Utah Research Foundation Beta-superfamily conotoxins
WO2002064740A2 (en) 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides

Also Published As

Publication number Publication date
CY1112839T1 (el) 2016-02-10
EP1572725A4 (en) 2008-09-24
ATE547424T1 (de) 2012-03-15
EP1572725B1 (en) 2012-02-29
AU2003302609B2 (en) 2008-03-20
AU2003302609B9 (en) 2008-05-15
WO2004050690A1 (en) 2004-06-17
US7851444B2 (en) 2010-12-14
SI1572725T1 (sl) 2012-08-31
JP4565087B2 (ja) 2010-10-20
EP1572725A1 (en) 2005-09-14
DK1572725T3 (da) 2012-06-18
AU2003302609A1 (en) 2004-06-23
CA2508129C (en) 2012-06-26
CA2508129A1 (en) 2004-06-17
US20060142201A1 (en) 2006-06-29
JP2006523181A (ja) 2006-10-12
NZ540518A (en) 2006-12-22
HK1080870A1 (en) 2006-05-04
PT1572725E (pt) 2012-05-28

Similar Documents

Publication Publication Date Title
US20090088389A1 (en) Novel x-conotoxin peptides (-ii)
DK2707014T3 (en) Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain
WO2008077194A1 (en) Receptor agonists
KR101046426B1 (ko) 항균 펩타이드 및 이를 포함하는 항균 조성물
ES2383358T3 (es) Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal
Zhang et al. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation
NZ540582A (en) Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
US8188048B2 (en) Combination therapy
Dutt Konar et al. Conformational Properties of Secondary Amino Acids: Replacement of Pipecolic Acid by N‐Methyl‐L‐alanine in Efrapeptin C
US7371810B1 (en) Tachykinin peptides, precursor peptides thereof and genes encoding the same
HK1080870B (en) Chi-conotoxin peptides having a n-terminal pyroglutamic acid
EA001000B1 (ru) Производные пептидов
HK1166808A (en) Chi-conotoxin peptides
ES2541308T3 (es) Agonistas y antagonistas completos y parciales altamente potentes del receptor de nociceptina/orfanina FQ
AU2013204309A1 (en) Therapeutic Compounds and Uses Thereof
CN1854151B (zh) 多巴胺转运蛋白拟肽抑制剂及其应用
WO2007012838A2 (en) Drug delivery system
KR20200102973A (ko) 지방산 항균펩타이드 및 이를 함유하는 항균 조성물